$GH
Guardant Health, Inc. Stock $gh

$gh Overview Financials Valuation SEC Filings Company Website

2021 Q2 Form 10-Q Financial Statement

#000157628021000080 Filed on August 05, 2021

Income Statement

Concept	2021 Q2	2020 Q2	2020 Q1
Revenue	$92.10M	$66.34M	$67.51M
YoY Change	38.84%	22.9%	84.18%
Cost Of Revenue	$29.93M	$22.44M	$20.51M
YoY Change	33.36%	33.33%	51.48%
Gross Profit	$62.17M	$43.90M	$47.00M
YoY Change	41.63%	18.2%	103.29%
Gross Profit Margin	67.51%	66.18%	69.62%
Selling, General & Admin	$96.09M	$62.20M	$44.90M
YoY Change	54.49%	89.19%	47.37%
% of Gross Profit	154.55%	141.69%	95.53%
Research & Development	$63.72M	$36.32M	$37.02M
YoY Change	75.46%	85.95%	126.87%
% of Gross Profit	102.49%	82.73%	78.76%
Depreciation & Amortization	$5.100M	$3.200M	$3.304M
YoY Change	59.38%	45.45%	40.36%
% of Gross Profit	8.2%	7.29%	7.03%
Operating Expenses	$159.8M	$98.52M	$81.92M
YoY Change	62.22%	87.98%	75.09%
Operating Profit	-$97.64M	-$54.62M	-$34.91M
YoY Change	78.77%	257.74%	47.53%
Interest Expense	$644.0K	$10.00K	$12.00K
YoY Change	6340.0%	-96.52%	-95.9%
% of Operating Profit
Other Income/Expense, Net	-$243.0K	$2.285M	-$209.0K
YoY Change	-110.63%	-4580.39%	-242.18%
Pretax Income	-$97.49M	-$49.71M	-$31.82M
YoY Change	96.14%	297.42%	49.19%
Income Tax	$83.00K	$34.00K	$14.00K
% Of Pretax Income
Net Earnings	-$97.58M	-$49.74M	-$31.83M
YoY Change	96.17%	340.17%	49.07%
Net Earnings / Revenue	-105.94%	-74.98%	-47.15%
Basic Earnings Per Share	-$0.96	-$0.57
Diluted Earnings Per Share	-$0.96	-$0.57	-$293.8K
COMMON SHARES
Basic Shares Outstanding	101.2M shares	96.01M shares	94.38M shares
Diluted Shares Outstanding	101.2M shares	96.01M shares

Balance Sheet

Concept	2021 Q2	2020 Q2	2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.792B	$937.8M	$520.1M
YoY Change	91.05%	71.88%	11.39%
Cash & Equivalents	$938.6M	$164.7M	$152.2M
Short-Term Investments	$853.1M	$773.2M	$367.9M
Other Short-Term Assets	$19.24M	$11.10M	$14.10M
YoY Change	73.3%	170.73%	127.42%
Inventory	$26.49M	$20.35M	$25.15M
Prepaid Expenses
Receivables	$53.67M	$41.02M	$48.02M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$1.891B	$1.010B	$607.4M
YoY Change	87.18%	67.2%	18.57%
LONG-TERM ASSETS
Property, Plant & Equipment	$89.74M	$57.00M	$46.69M
YoY Change	57.45%	63.73%	52.66%
Goodwill	$3.290M	$3.290M	$3.290M
YoY Change	0.0%
Intangibles	$15.19M	$17.15M	$17.68M
YoY Change	-11.42%	90.81%
Long-Term Investments	$55.37M	$146.1M	$238.2M
YoY Change	-62.1%	-47.31%	819.69%
Other Assets	$36.28M	$5.124M	$4.721M
YoY Change	608.12%	62.2%	64.95%
Total Long-Term Assets	$400.8M	$267.2M	$340.8M
YoY Change	49.99%	-20.41%	409.26%
TOTAL ASSETS
Total Short-Term Assets	$1.891B	$1.010B	$607.4M
Total Long-Term Assets	$400.8M	$267.2M	$340.8M
Total Assets	$2.292B	$1.278B	$948.2M
YoY Change	79.4%	35.91%	63.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$21.40M	$15.98M	$24.38M
YoY Change	33.89%	1.8%	240.33%
Accrued Expenses	$32.00M	$24.06M	$23.07M
YoY Change	33.02%	116.87%	152.52%
Deferred Revenue	$8.480M	$11.49M
YoY Change	-26.16%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$96.61M	$70.05M	$82.32M
YoY Change	37.92%	22.79%	70.82%
LONG-TERM LIABILITIES
Long-Term Debt	$1.134B	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Other Long-Term Liabilities	$2.486M	$1.382M	$1.459M
YoY Change	79.88%	6.06%	872.67%
Total Long-Term Liabilities	$2.486M	$1.382M	$1.459M
YoY Change	79.88%	6.06%	872.67%
TOTAL LIABILITIES
Total Short-Term Liabilities	$96.61M	$70.05M	$82.32M
Total Long-Term Liabilities	$2.486M	$1.382M	$1.459M
Total Liabilities	$1.444B	$112.5M	$117.6M
YoY Change	1183.39%	44.82%	82.15%
SHAREHOLDERS EQUITY
Retained Earnings	-$809.4M	-$435.2M	-$380.5M
YoY Change	85.99%	38.24%	37.93%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$788.1M	$1.115B	$785.1M
YoY Change
Total Liabilities & Shareholders Equity	$2.292B	$1.278B	$948.2M
YoY Change	79.4%	35.91%	63.71%

Cashflow Statement

Concept	2021 Q2	2020 Q2	2020 Q1
OPERATING ACTIVITIES
Net Income	-$97.58M	-$49.74M	-$31.83M
YoY Change	96.17%	340.17%	49.07%
Depreciation, Depletion And Amortization	$5.100M	$3.200M	$3.304M
YoY Change	59.38%	45.45%	40.36%
Cash From Operating Activities	-$62.59M	-$23.37M	-$13.28M
YoY Change	167.84%	68.86%	208.67%
INVESTING ACTIVITIES
Capital Expenditures	-$18.67M	-$9.510M	$9.598M
YoY Change	96.33%	212.83%	254.82%
Acquisitions
YoY Change
Other Investing Activities	$145.7M	-$316.0M	$48.29M
YoY Change	-146.11%	-0.45%	167.83%
Cash From Investing Activities	$127.1M	-$325.6M	$20.80M
YoY Change	-139.03%	1.57%	35.72%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	4.906M	361.3M	$1.466M
YoY Change	-98.64%	1.76%	-35.93%
NET CHANGE
Cash From Operating Activities	-62.59M	-23.37M	-$13.28M
Cash From Investing Activities	127.1M	-325.6M	$20.80M
Cash From Financing Activities	4.906M	361.3M	$1.466M
Net Change In Cash	69.38M	12.40M	$9.011M
YoY Change	459.5%	-40.1%	-31.97%
FREE CASH FLOW
Cash From Operating Activities	-$62.59M	-$23.37M	-$13.28M
Capital Expenditures	-$18.67M	-$9.510M	$9.598M
Free Cash Flow	-$43.92M	-$13.86M	-$22.88M
YoY Change	216.9%	28.33%	226.48%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Central Index Key EntityCentralIndexKey	0001576280
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	gh:AccountingStandardsUpdate202006Member
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2021-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38683
	dei	Entity Registrant Name EntityRegistrantName	GUARDANT HEALTH, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-4139254
	dei	Entity Address Address Line1 EntityAddressAddressLine1	505 Penobscot Dr.
	dei	Entity Address City Or Town EntityAddressCityOrTown	Redwood City
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94063
	dei	City Area Code CityAreaCode	855
	dei	Local Phone Number LocalPhoneNumber	698-8887
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.00001
	dei	Trading Symbol TradingSymbol	GH
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	101298669	shares
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	938590000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	832977000	USD
CY2021Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	853072000	USD
CY2020Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	961903000	USD
CY2021Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	53667000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	53299000	USD
CY2021Q2	us-gaap	Inventory Net InventoryNet	26494000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	22716000	USD
CY2021Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	19236000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	17466000	USD
CY2021Q2	us-gaap	Assets Current AssetsCurrent	1891059000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	1888361000	USD
CY2021Q2	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	55368000	USD
CY2020Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	246597000	USD
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	89737000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	62782000	USD
CY2021Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	200958000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	37343000	USD
CY2021Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	15189000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	16155000	USD
CY2021Q2	us-gaap	Goodwill Goodwill	3290000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	3290000	USD
CY2021Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	36284000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	17253000	USD
CY2021Q2	us-gaap	Assets Assets	2291885000	USD
CY2020Q4	us-gaap	Assets Assets	2271781000	USD
CY2021Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	21399000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	7340000	USD
CY2021Q2	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	34735000	USD
CY2020Q4	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	28280000	USD
CY2021Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	31998000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	22639000	USD
CY2021Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	8480000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	8550000	USD
CY2021Q2	us-gaap	Liabilities Current LiabilitiesCurrent	96612000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	66809000	USD
CY2021Q2	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	1133539000	USD
CY2020Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	806292000	USD
CY2021Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	211783000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	41565000	USD
CY2021Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2486000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1520000	USD
CY2021Q2	us-gaap	Liabilities Liabilities	1444420000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	916186000	USD
CY2021Q2	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	59400000	USD
CY2020Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	57100000	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2021Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	101265100	shares
CY2021Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	101265100	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	100213985	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	100213985	shares
CY2021Q2	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	1000	USD
CY2020Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	1000	USD
CY2021Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1597419000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1902389000	USD
CY2021Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	33000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	2697000	USD
CY2021Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-809388000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-606592000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	788065000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1298495000	USD
CY2021Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2291885000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2271781000	USD
CY2021Q2	gh	Revenuefrom Precision Oncology Testing RevenuefromPrecisionOncologyTesting	72604000	USD
CY2020Q2	gh	Revenuefrom Precision Oncology Testing RevenuefromPrecisionOncologyTesting	50991000	USD
	gh	Revenuefrom Precision Oncology Testing RevenuefromPrecisionOncologyTesting	136333000	USD
	gh	Revenuefrom Precision Oncology Testing RevenuefromPrecisionOncologyTesting	111237000	USD
CY2021Q2	gh	Revenuefrom Development Services RevenuefromDevelopmentServices	19497000	USD
CY2020Q2	gh	Revenuefrom Development Services RevenuefromDevelopmentServices	15344000	USD
	gh	Revenuefrom Development Services RevenuefromDevelopmentServices	34433000	USD
	gh	Revenuefrom Development Services RevenuefromDevelopmentServices	22608000	USD
CY2021Q2	us-gaap	Revenues Revenues	92101000	USD
CY2020Q2	us-gaap	Revenues Revenues	66335000	USD
	us-gaap	Revenues Revenues	170766000	USD
	us-gaap	Revenues Revenues	133845000	USD
CY2021Q2	gh	Costsof Precision Oncology Testing CostsofPrecisionOncologyTesting	24887000	USD
CY2020Q2	gh	Costsof Precision Oncology Testing CostsofPrecisionOncologyTesting	17809000	USD
	gh	Costsof Precision Oncology Testing CostsofPrecisionOncologyTesting	48477000	USD
	gh	Costsof Precision Oncology Testing CostsofPrecisionOncologyTesting	36000000	USD
CY2021Q2	gh	Costof Development Services CostofDevelopmentServices	5040000	USD
CY2020Q2	gh	Costof Development Services CostofDevelopmentServices	4626000	USD
	gh	Costof Development Services CostofDevelopmentServices	10197000	USD
	gh	Costof Development Services CostofDevelopmentServices	6941000	USD
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	63724000	USD
CY2020Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	36319000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	119232000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	73335000	USD
CY2021Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	47716000	USD
CY2020Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	25015000	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	82054000	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	50130000	USD
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	48376000	USD
CY2020Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	37186000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	116311000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	56971000	USD
CY2021Q2	us-gaap	Costs And Expenses CostsAndExpenses	189743000	USD
CY2020Q2	us-gaap	Costs And Expenses CostsAndExpenses	120955000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	376271000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	223377000	USD
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-97642000	USD
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-54620000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-205505000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-89532000	USD
CY2021Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	1037000	USD
CY2020Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	2640000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	2588000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	5958000	USD
CY2021Q2	us-gaap	Interest Expense InterestExpense	644000	USD
CY2020Q2	us-gaap	Interest Expense InterestExpense	10000	USD
	us-gaap	Interest Expense InterestExpense	1290000	USD
	us-gaap	Interest Expense InterestExpense	22000	USD
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-243000	USD
CY2020Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2285000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-533000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2076000	USD
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-97492000	USD
CY2020Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-49705000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-204740000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-81520000	USD
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	83000	USD
CY2020Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	34000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	193000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	48000	USD
CY2021Q2	us-gaap	Profit Loss ProfitLoss	-97575000	USD
CY2020Q2	us-gaap	Profit Loss ProfitLoss	-49739000	USD
	us-gaap	Profit Loss ProfitLoss	-204933000	USD
	us-gaap	Profit Loss ProfitLoss	-81568000	USD
CY2021Q2	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	0	USD
CY2020Q2	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	4900000	USD
	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	2300000	USD
	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	800000	USD
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-97575000	USD
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-97575000	USD
CY2020Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-54639000	USD
CY2020Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-54639000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-207233000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-207233000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-82368000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-82368000	USD
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.96
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.96
CY2020Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.57
CY2020Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.57
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.05
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.05
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.87
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.87
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	101172000	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	101172000	shares
CY2020Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	96011000	shares
CY2020Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	96011000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	101064000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	101064000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	95196000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	95196000	shares
CY2021Q2	us-gaap	Profit Loss ProfitLoss	-97575000	USD
CY2020Q2	us-gaap	Profit Loss ProfitLoss	-49739000	USD
	us-gaap	Profit Loss ProfitLoss	-204933000	USD
	us-gaap	Profit Loss ProfitLoss	-81568000	USD
CY2021Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-878000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-2338000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1584000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	4233000	USD
CY2021Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	7000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	25000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-1080000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	48000	USD
CY2021Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-871000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-2313000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-2664000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	4281000	USD
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-98446000	USD
CY2020Q2	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-52052000	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-207597000	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-77287000	USD
CY2021Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	0	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	4900000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	2300000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	800000	USD
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-98446000	USD
CY2020Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-56952000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-209897000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-78087000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	847046000	USD
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	926000	USD
CY2021Q2	gh	Stock Issued During Period Value Stock Options Exercised Early StockIssuedDuringPeriodValueStockOptionsExercisedEarly	13000	USD
CY2021Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	5401000	USD
CY2021Q2	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	1382000	USD
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	34507000	USD
CY2021Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-871000	USD
CY2021Q2	us-gaap	Profit Loss ProfitLoss	-97575000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	788065000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	785113000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	1130000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	354600000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2044000	USD
CY2020Q2	gh	Stock Issued During Period Value Stock Options Exercised Early StockIssuedDuringPeriodValueStockOptionsExercisedEarly	13000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	3956000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	25815000	USD
CY2020Q2	us-gaap	Reclassifications Of Temporary To Permanent Equity ReclassificationsOfTemporaryToPermanentEquity	-4900000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-2313000	USD
CY2020Q2	us-gaap	Profit Loss ProfitLoss	-49739000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	1114589000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1298495000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	5388000	USD
	gh	Stock Issued During Period Value Stock Options Exercised Early StockIssuedDuringPeriodValueStockOptionsExercisedEarly	26000	USD
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	5401000	USD
	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	74958000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	89576000	USD
	us-gaap	Reclassifications Of Temporary To Permanent Equity ReclassificationsOfTemporaryToPermanentEquity	-2300000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-2664000	USD
	us-gaap	Profit Loss ProfitLoss	-204933000	USD
	gh	Stock Issued During Period Value Stock Options Exercised Early StockIssuedDuringPeriodValueStockOptionsExercisedEarly	26000	USD
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	3956000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	788065000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	798393000	USD
	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	1130000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	354600000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3548000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	32153000	USD
	us-gaap	Reclassifications Of Temporary To Permanent Equity ReclassificationsOfTemporaryToPermanentEquity	-800000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	4281000	USD
	us-gaap	Profit Loss ProfitLoss	-81568000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	1114589000	USD
	us-gaap	Profit Loss ProfitLoss	-204933000	USD
	us-gaap	Profit Loss ProfitLoss	-81568000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	10637000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	7109000	USD
	gh	Non Cash Operating Lease Costs NonCashOperatingLeaseCosts	10839000	USD
	gh	Non Cash Operating Lease Costs NonCashOperatingLeaseCosts	3386000	USD
	gh	Charge Of In Process Research And Development ChargeOfInProcessResearchAndDevelopment	0	USD
	gh	Charge Of In Process Research And Development ChargeOfInProcessResearchAndDevelopment	8500000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	875000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-190000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	89576000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	32153000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1282000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	0	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-6528000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1065000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-8000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	19000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	368000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-6894000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3778000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5173000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3036000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-438000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	4282000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	242000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	7112000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2476000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	6455000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-31000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	7304000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-1820000	USD
	gh	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-3033000	USD
	gh	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-3881000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-70000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-792000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-78884000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-36647000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	126163000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	465302000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	355730000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	369000	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	784000	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-65044000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	362786000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-1080000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	49000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	105928000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	21443000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	832977000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	143228000	USD
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	938905000	USD
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	164671000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	170911000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	11373000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	10289000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	418110000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	197548000	USD
	gh	Payments To Acquire Equity Securities Fvni PaymentsToAcquireEquitySecuritiesFVNI	12750000	USD
	gh	Payments To Acquire Equity Securities Fvni PaymentsToAcquireEquitySecuritiesFVNI	0	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	28261000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	19105000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	17886000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	250936000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-304745000	USD
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	91000	USD
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	79000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	5388000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3548000	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	5401000	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	3956000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	74958000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	5396000	USD
	gh	Equity Securities Fvni Incurred But Not Yet Paid EquitySecuritiesFVNIIncurredButNotYetPaid	587000	USD
	gh	Equity Securities Fvni Incurred But Not Yet Paid EquitySecuritiesFVNIIncurredButNotYetPaid	0	USD
	gh	Offering Costs Incurred But Not Yet Paid OfferingCostsIncurredButNotYetPaid	0	USD
	gh	Offering Costs Incurred But Not Yet Paid OfferingCostsIncurredButNotYetPaid	761000	USD
	gh	Property Plant And Equipment Acquired Under Finance Leases PropertyPlantAndEquipmentAcquiredUnderFinanceLeases	236000	USD
	gh	Property Plant And Equipment Acquired Under Finance Leases PropertyPlantAndEquipmentAcquiredUnderFinanceLeases	0	USD
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	938590000	USD
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	164671000	USD
CY2021Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	315000	USD
CY2020Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	0	USD
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	938905000	USD
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	164671000	USD
	gh	Equity Security Fvni Impairment Or Adjustments To Carrying Value EquitySecurityFVNIImpairmentOrAdjustmentsToCarryingValue	0	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the condensed consolidated financial statements, as well as the reported amounts of revenues and expenses during the periods presented. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Estimates are used in several areas including, but not limited to, estimation of variable consideration, estimation of credit losses, standalone selling price allocation included in contracts with multiple performance obligations, goodwill and identifiable intangible assets, stock-based compensation, incremental borrowing rate for operating leases, contingencies, certain inputs into the provision for income taxes, including related reserves, valuation of non-</span></div>marketable securities, valuation of redeemable noncontrolling interest, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management’s estimates. The extent to which the coronavirus 2019, or COVID-19 pandemic will ultimately impact the Company’s business, results of operations, financial conditions, or cash flows continues to be highly uncertain. The severity of the impact on the Company's business for the remainder of calendar year 2021 and beyond will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic, and the impact of any variants of the virus, the extent and severity of the impact on the Company's customers and suppliers, the continued disruption to demand for the Company's products and services, and the impact of the global business and economic environment on liquidity and the availability of capital, all of which are uncertain and cannot be predicted.
CY2021Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	300000	USD
CY2020Q4	us-gaap	Restricted Cash RestrictedCash	0	USD
CY2021Q2	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	13300000	USD
CY2020Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	0	USD
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Concentration of Risk</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its portfolio of cash equivalents held at one commercial bank and investments in marketable securities. The Company limits its exposure to credit losses by investing in money market funds through a U.S. bank with high credit ratings. The Company’s cash may consist of deposits held with banks that may at times exceed federally insured limits, however, its exposure to credit risk in the event of default by the financial institution is limited to the extent of amounts recorded on the condensed consolidated balance sheets. The Company performs evaluations of the relative credit standing of these financial institutions to limit the amount of credit exposure. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also invests in investment-grade debt instruments and has policy limits for the amount it can invest in any one type of security, except for securities issued or guaranteed by the U.S. government. The goals of the Company’s investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after-tax rate of return. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, investment type and issuer, as a result, the Company is not exposed to any significant concentrations of credit risk from these financial instruments.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its accounts receivable. The majority of the Company’s accounts receivable arises from the provision of precision oncology services and development services and other in the United States and are primarily with biopharmaceutical companies with high credit ratings. The Company has not experienced any material losses related to receivables from individual customers, or groups of customers. The Company does not require collateral. Accounts receivable are recorded at net amount.</span></div>The Company is also subject to credit risk from its other receivables and other assets. The Company's other receivables and other assets include payments due from a third-party in relation to the settlement of a patent dispute reached in August 2020 for $8.0 million payable over a period of 6 years. In December 2020, the Company received the first installment payment of $1.0 million. The Company has evaluated and recorded a credit loss for the remaining $7.0 million considering the third-party's credit worthiness and lack of financial history.
CY2020Q3	gh	Contractual Receivables Before Allowance For Credit Loss ContractualReceivablesBeforeAllowanceForCreditLoss	8000000.0	USD
CY2020Q3	gh	Contractual Receivables Term ContractualReceivablesTerm	P6Y
CY2020Q4	gh	Proceeds From Contractual Receivable ProceedsFromContractualReceivable	1000000.0	USD
CY2020Q4	gh	Contractual Receivables Credit Loss Expense Reversal Noncurrent ContractualReceivablesCreditLossExpenseReversalNoncurrent	7000000.0	USD
CY2021Q2	gh	Contractual Receivables Before Allowance For Credit Loss Gross Current ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent	1100000	USD
CY2020Q4	gh	Contractual Receivables Before Allowance For Credit Loss Gross Current ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent	0	USD
CY2020Q4	gh	Contractual Receivables Allowance For Credit Loss Current ContractualReceivablesAllowanceForCreditLossCurrent	0	USD
CY2021Q1	gh	Contractual Receivables Allowance For Credit Loss Current ContractualReceivablesAllowanceForCreditLossCurrent	0	USD
	gh	Contractual Receivables Credit Loss Expense Reversal Current ContractualReceivablesCreditLossExpenseReversalCurrent	0	USD
CY2021Q2	gh	Contractual Receivables Credit Loss Expense Reversal Current ContractualReceivablesCreditLossExpenseReversalCurrent	0	USD
	gh	Contractual Receivables Credit Loss Reclassification Current ContractualReceivablesCreditLossReclassificationCurrent	1100000	USD
CY2021Q2	gh	Contractual Receivables Credit Loss Reclassification Current ContractualReceivablesCreditLossReclassificationCurrent	1100000	USD
CY2021Q2	gh	Contractual Receivables Allowance For Credit Loss Current ContractualReceivablesAllowanceForCreditLossCurrent	1100000	USD
CY2021Q2	gh	Contractual Receivables Allowance For Credit Loss Current ContractualReceivablesAllowanceForCreditLossCurrent	1100000	USD
CY2021Q2	gh	Contractual Receivables After Allowance For Credit Loss Net Current ContractualReceivablesAfterAllowanceForCreditLossNetCurrent	0	USD
CY2020Q4	gh	Contractual Receivables After Allowance For Credit Loss Net Current ContractualReceivablesAfterAllowanceForCreditLossNetCurrent	0	USD
CY2021Q2	gh	Contractual Receivables Before Allowance For Credit Loss Gross Noncurrent ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent	5900000	USD
CY2020Q4	gh	Contractual Receivables Before Allowance For Credit Loss Gross Noncurrent ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent	7000000	USD
CY2020Q4	gh	Contractual Receivables Allowance For Credit Loss Noncurrent ContractualReceivablesAllowanceForCreditLossNoncurrent	7000000	USD
CY2021Q1	gh	Contractual Receivables Allowance For Credit Loss Noncurrent ContractualReceivablesAllowanceForCreditLossNoncurrent	7000000	USD
	gh	Contractual Receivables Credit Loss Expense Reversal Noncurrent ContractualReceivablesCreditLossExpenseReversalNoncurrent	0	USD
CY2021Q2	gh	Contractual Receivables Credit Loss Expense Reversal Noncurrent ContractualReceivablesCreditLossExpenseReversalNoncurrent	0	USD
	gh	Contractual Receivables Credit Loss Reclassification Noncurrent ContractualReceivablesCreditLossReclassificationNoncurrent	-1100000	USD
CY2021Q2	gh	Contractual Receivables Credit Loss Reclassification Noncurrent ContractualReceivablesCreditLossReclassificationNoncurrent	-1100000	USD
CY2021Q2	gh	Contractual Receivables Allowance For Credit Loss Noncurrent ContractualReceivablesAllowanceForCreditLossNoncurrent	5900000	USD
CY2021Q2	gh	Contractual Receivables Allowance For Credit Loss Noncurrent ContractualReceivablesAllowanceForCreditLossNoncurrent	5900000	USD
CY2021Q2	gh	Contractual Receivables After Allowance For Credit Loss Net Noncurrent ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent	0	USD
CY2020Q4	gh	Contractual Receivables After Allowance For Credit Loss Net Noncurrent ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent	0	USD
CY2021Q2	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	24800000	USD
CY2020Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	15600000	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	USD
CY2021Q2	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	0	USD
CY2021Q2	us-gaap	Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice	9600000	USD
CY2020Q2	us-gaap	Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice	9100000	USD
	us-gaap	Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice	14600000	USD
	us-gaap	Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice	16500000	USD
CY2021Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	8500000	USD
CY2020Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	8600000	USD
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	6400000	USD
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	7600000	USD
	gh	Variable Interest Entity Threshold Percentageof Fair Valuethatis No Less Than Internal Rateof Return VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn	0.20
	gh	Variable Interest Entity Fair Value Of Joint Venture Threshold For Share Purchase VariableInterestEntityFairValueOfJointVentureThresholdForSharePurchase	0.40
	gh	Variable Interest Entity Fair Value Of Joint Venture Threshold For Share Purchase VariableInterestEntityFairValueOfJointVentureThresholdForSharePurchase	0.40
CY2021Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	134008000	USD
CY2021Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	6564000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	97127000	USD
CY2021Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	44271000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	34345000	USD
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	89737000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	62782000	USD
CY2021Q2	us-gaap	Depreciation Depreciation	5100000	USD
CY2020Q2	us-gaap	Depreciation Depreciation	3200000	USD
	us-gaap	Depreciation Depreciation	9600000	USD
	us-gaap	Depreciation Depreciation	6200000	USD
CY2021Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	7547000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	6632000	USD
CY2021Q2	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	4500000	USD
CY2020Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	4634000	USD
CY2021Q2	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	179000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3397000	USD
CY2021Q2	gh	Accrued Clinical Trialsand Studies AccruedClinicalTrialsandStudies	2625000	USD
CY2020Q4	gh	Accrued Clinical Trialsand Studies AccruedClinicalTrialsandStudies	1264000	USD
CY2021Q2	gh	Estimated Litigation Liability Legal Fees Current EstimatedLitigationLiabilityLegalFeesCurrent	2081000	USD
CY2020Q4	gh	Estimated Litigation Liability Legal Fees Current EstimatedLitigationLiabilityLegalFeesCurrent	2875000	USD
CY2021Q2	gh	Accrued Expenses Propertyand Equipment Current AccruedExpensesPropertyandEquipmentCurrent	2383000	USD
CY2020Q4	gh	Accrued Expenses Propertyand Equipment Current AccruedExpensesPropertyandEquipmentCurrent	1156000	USD
CY2020Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	146000	USD
CY2021Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	6119000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2535000	USD
CY2021Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	31998000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	22639000	USD
CY2021Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	613000	USD
CY2021Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	5000	USD
CY2021Q2	gh	Cash Cash Equivalentsand Debt Securities Fair Value CashCashEquivalentsandDebtSecuritiesFairValue	1746554000	USD
CY2021Q2	gh	Debt Securities Availableforsaleand Cashand Cash Equivalents Amortized Cost DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost	1745946000	USD
CY2020Q4	gh	Debt Securities Availableforsaleand Cashand Cash Equivalents Amortized Cost DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost	1826825000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	2339000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	35000	USD
CY2020Q4	gh	Cash Cash Equivalentsand Debt Securities Fair Value CashCashEquivalentsandDebtSecuritiesFairValue	1829129000	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	16986000	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	3397000	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	13589000	USD
CY2021Q2	us-gaap	Goodwill Goodwill	3290000	USD
CY2021Q2	us-gaap	Goodwill Goodwill	3290000	USD
CY2021Q2	gh	Intangible Assets Gross Including Goodwill IntangibleAssetsGrossIncludingGoodwill	21876000	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	3397000	USD
CY2021Q2	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	18479000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	16986000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2431000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	14555000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	3290000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	3290000	USD
CY2020Q4	gh	Intangible Assets Gross Including Goodwill IntangibleAssetsGrossIncludingGoodwill	21876000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2431000	USD
CY2020Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	19445000	USD
CY2021Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	500000	USD
CY2020Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	500000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1000000.0	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	800000	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	982000	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	1947000	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	1947000	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	1952000	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	1705000	USD
CY2020Q4	gh	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Hedges AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtHedges	90000000.0	USD
CY2021Q2	gh	Finite Lived Intangible Assets Amortization Expense After Year Four FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour	5056000	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	13589000	USD
CY2020Q4	gh	Convertible Debt Hedge Strike Price ConvertibleDebtHedgeStrikePrice	182.60
CY2020Q4	gh	Convertible Debt Hedge Share Price Premium Percentage ConvertibleDebtHedgeSharePricePremiumPercentage	0.75
CY2020Q4	us-gaap	Share Price SharePrice	104.34
CY2021Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	6900000	USD
CY2020Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	1900000	USD
	us-gaap	Operating Lease Expense OperatingLeaseExpense	10800000	USD
	us-gaap	Operating Lease Expense OperatingLeaseExpense	3400000	USD
CY2021Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P10Y3M18D
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y6M
CY2021Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0414
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0807
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	5398000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	21454000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	28976000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	31529000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	32084000	USD
CY2021Q2	gh	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	177402000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	296843000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	54792000	USD
CY2021Q2	gh	Lessee Operating Lease Liability Lease Incentive LesseeOperatingLeaseLiabilityLeaseIncentive	22721000	USD
CY2021Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	219330000	USD
CY2017Q4	us-gaap	Gain Contingency Patents Allegedly Infringed Upon Number GainContingencyPatentsAllegedlyInfringedUponNumber	4	patent
CY2018Q3	us-gaap	Gain Contingency Patents Allegedly Infringed Upon Number GainContingencyPatentsAllegedlyInfringedUponNumber	4	segment
	us-gaap	Dividends Common Stock DividendsCommonStock	0	USD
CY2020	us-gaap	Dividends Common Stock DividendsCommonStock	0	USD
CY2021Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	13939220	shares
CY2020Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	11344620	shares
CY2020Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	4312500	shares
CY2020Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	84.00
CY2020Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	354600000	USD
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	2091339	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1819223	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3101181	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	15.80
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y10M24D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	350670000	USD
	gh	Sharebased Compensation Arrangementby Sharebased Payment Award Options Annual Increase In Shares Available SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable	3689000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	60677	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	142.73
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	371711	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	14.34
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	86241	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	47.02
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	5928052	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2703906	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	17.86
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y6M
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	288749000	USD
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	9.16
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y1M6D
CY2021Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	240569000	USD
	gh	Sharebased Compensation Arrangementby Sharebased Payment Award Options Annual Increase In Shares Available SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable	3689000	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	81.79
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	44.61
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	84.02
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	45.52
CY2021Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	19700000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y8M12D
CY2021Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	34507000	USD
CY2020Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	25815000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	89576000	USD
	us-gaap	Profit Loss ProfitLoss	-204933000	USD
	us-gaap	Profit Loss ProfitLoss	-81568000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	32153000	USD
CY2021Q2	us-gaap	Profit Loss ProfitLoss	-97575000	USD
CY2020Q2	us-gaap	Profit Loss ProfitLoss	-49739000	USD
CY2021Q2	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	0	USD
CY2020Q2	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	4900000	USD
	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	2300000	USD
	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	800000	USD
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-97575000	USD
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-97575000	USD
CY2020Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-54639000	USD
CY2020Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.57
CY2020Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-54639000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-207233000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-207233000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-82368000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-82368000	USD
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.96
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.96
CY2020Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.57
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.05
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.05
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.87
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.87
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	101172000	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	101172000	shares
CY2020Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	96011000	shares
CY2020Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	96011000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	101064000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	101064000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	95196000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	95196000	shares
CY2021Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14813000	shares
CY2020Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5997000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15090000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5451000	shares
CY2021Q2	us-gaap	Revenues Revenues	92101000	USD
CY2020Q2	us-gaap	Revenues Revenues	66335000	USD
	us-gaap	Revenues Revenues	170766000	USD
	us-gaap	Revenues Revenues	133845000	USD

Files In Submission

Name	View Source	Status
0001576280-21-000080-index-headers.html	Edgar Link	pending
0001576280-21-000080-index.html	Edgar Link	pending
0001576280-21-000080.txt	Edgar Link	pending
0001576280-21-000080-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
gh-0630x2021x10qxex311.htm	Edgar Link	pending
gh-0630x2021x10qxex312.htm	Edgar Link	pending
gh-0630x2021x10qxex321.htm	Edgar Link	pending
gh-0630x2021x10qxex322.htm	Edgar Link	pending
gh-20210630.htm	Edgar Link	pending
gh-20210630.xsd	Edgar Link	pending
gh-20210630_cal.xml	Edgar Link	unprocessable
gh-20210630_def.xml	Edgar Link	unprocessable
gh-20210630_htm.xml	Edgar Link	completed
gh-20210630_lab.xml	Edgar Link	unprocessable
gh-20210630_pre.xml	Edgar Link	unprocessable
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$GH
Guardant Health, Inc. Stock $gh

2021 Q2 Form 10-Q Financial Statement

#000157628021000080 Filed on August 05, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GH Guardant Health, Inc. Stock $gh

2021 Q2 Form 10-Q Financial Statement

#000157628021000080 Filed on August 05, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GH
Guardant Health, Inc. Stock $gh